The FDA To Give This Biotech’s Potential Blockbuster Alzheimer’s Drug A Rapid Review

If the biotech highlighted in today’s article ends up getting its drug approved, it would be the first Alzheimer’s treatment that actually reduces the cognitive decline of the devastating disease – and the FDA recently indicated that it would give the experimental drug a more speedy review, causing shares of the firm to climb about 9%. For more on the biotech in question and its potential blockbuster Alzheimer’s drug, CLICK HERE.